Solventum SOLV reported first-quarter 2025 adjusted earnings per share (EPS) of $1.34, which beat the Zacks Consensus Estimate of $1.19 by 12.6%. The bottom line declined 35.6% year over year. GAAP EPS in the quarter was 78 cents, down 43.1% from the year-ago quarter’s level. (Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.) Revenue Details The company reported revenues of $2.07 billion, up 2.6% reportedly from the prior-year recorded number. Organically, sales were up 4.3%. The metric beat the Zacks Consensus Estimate by 3.4%. Organic sales growth was primarily driven by positive performance from all segments, primarily MedSurg and HIS. Shares of the company were up 1.4% during after-hours trading on May 9, following a strong quarterly performance. The stock has risen 20.8% since its IPO on April 1, 2024, against the industry’s decline of 17.3%. The S&P 500 Index has gained 17.8% in the same period.Zacks Investment Research Image Source: Zacks Investment Research Segmental Details MedSurg Revenues from this segment totaled $1.16 billion, up 3.4% reportedly and 8.2% organically year over year. Organic growth was driven by strong volumes in IV site management and hospital consumables. Sales also benefited from the adoption of single-use negative pressure wound therapy. Dental Solutions Revenues totaled $328 million, down 2.1% year over year reportedly but up 0.4% organically. Weak performance of Core Orthodontics amid market-driven headwinds was offset by strong sales of Restorative, including benefits of recent product launches — Filtek Easy Match and ClinPro Clear. HIS Revenues from this segment amounted to $329 million, up 3.6% reportedly and 3.9% organically on a year-over-year basis. Organic growth was driven by the continued adoption of 360 Encompass revenue cycle management. Purification and Filtration Revenues from this segment amounted to $242 million, down 0.9% year over year reportedly but up 2.2% organically. Growth was driven by continued strength in bioprocessing filtration and industrial filtration, offsetting declines in Membrane OEM. Margins Adjusted gross profit was $1.15 billion, down 1.9% year over year. As a percentage of revenues, the adjusted gross margin was 55.6%, down approximately 260 bps from the prior-year quarter’s figure. Selling, general and administrative expenses totaled $769 million, up 29% year over year. Research and development expenses totaled $193 million, down 1% on a year-over-year basis. Adjusted operating income totaled $407 million, down 15.9% year over year. As a percentage of revenues, the adjusted operating margin was 19.7%, down approximately 430 bps from the prior-year quarter’s figure. Story Continues Financial Position Solventum exited the first quarter with cash, cash equivalents and investments of $534 million compared with $762 million in the previous quarter. Total assets increased to $14.52 billion from $14.46 billion in the previous quarter. 2025 Guidance Solventum raised its sales guidance for 2025. Solventum now expects organic sales growth of 1.5-2.5% (2-3% excluding ~50bps of SKU Exit impact), up from the previous guidance of 1-2%. The Zacks Consensus Estimate for the same is pegged at $8.25 billion. SOLV continues to expect adjusted EPS in the band of $5.45-$5.65. The Zacks Consensus Estimate for earnings is pinned at $5.48 per share. Solventum Corporation Price, Consensus and EPS SurpriseSolventum Corporation Price, Consensus and EPS Surprise Solventum Corporation price-consensus-eps-surprise-chart | Solventum Corporation Quote Our Take Solventum exited the first quarter on a strong note. Both the top and bottom lines beat their respective estimates. The organic growth at SOLV’s largest segment (in terms of revenues), MedSurg, looks promising. The trend is likely to continue in the upcoming quarters as well due to continued demand for its products. Strong adoption of 360 Encompass revenue cycle management is likely to aid sales growth for the HIS segment in the future. However, a year-over-year decline in adjusted EPS does not bode well. The contraction in gross and operating margins also raises concern. SOLV is undergoing a three-phase restructuring program after its separation from 3M in 2023. Phase 1 is expected to be completed within 12-24 months, focusing on debt reduction, portfolio optimization and operational efficiency. These initiatives look promising for the company’s long-term prospects. SOLV’s Zacks Rank and Other Key Picks Solventum currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the same medical industry are AxoGen AXGN, Cardinal Health CAH and CVS Health CVS. AxoGen, carrying a Zacks Rank #2 at present, has an estimated growth rate of 76.9% for 2025. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. AXGN’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 113.33%. AXGN’s shares have declined 23.6% so far this year. Cardinal Health, carrying a Zacks Rank of 2 at present, has an estimated growth rate of 11.8% for fiscal 2026. CAH’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 10.30%. CAH’s shares have gained 24.5% so far this year. CVS Health, carrying a Zacks Rank #2 at present, has an estimated earnings growth rate of 11.4% for 2025. The company’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 18.08%. CVS’ shares have gained 51.2% so far this year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH):Free Stock Analysis Report CVS Health Corporation (CVS):Free Stock Analysis Report AxoGen, Inc. (AXGN):Free Stock Analysis Report Solventum Corporation (SOLV):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...